Triumph Capital Management Transcode Therapeutics, Inc. Call Options Transaction History

Triumph Capital Management

  • $234 Million
  • Q1 2024

Call Options

0 transactions
Quarter Operation Price Per call calls change calls Held SEC Form
No transaction found.

Others Institutions Holding RNAZ

# of Institutions
1
Shares Held
6.5K
Call Options Held
0
Put Options Held
0
View Full List

About Transcode Therapeutics, Inc.

RNAZ Quotes by TradingView
  • Ticker RNAZ
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 12,977,200
  • Market Cap $4.93M
  • Description
  • TransCode Therapeutics, Inc., a biopharmaceutical company, engages in the development and commercialization of drugs and diagnostics for treating and identifying metastatic disease. Its lead therapeutic candidate, TTX-MC138, is a preclinical stage product for the treatment of metastatic cancer. The company's products in preclinical programs incl...
More about RNAZ
Track This Portfolio

Track Triumph Capital Management Portfolio

Follow Triumph Capital Management and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Triumph Capital Management, based on Form 13F filings with the SEC.

News

Stay updated on Triumph Capital Management with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email